Skip to main content
TipRanks
Go Ultimate75% OFF

Community Health (CG5) AI Stock Analysis

0 Followers
CH:CG5

Community Health

(BX Swiss:CG5)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Same-store volume growthBroad same-store growth across revenue, admissions, clinics, and imaging indicates continued demand for the company’s core services. Sustained volume expansion can improve hospital utilization and support revenue resilience, even while payer mix and procedure composition remain challenging.
Negative Factors
Stressed balance sheetPersistent negative equity and substantial debt reduce financial flexibility and leave less capacity to absorb operating setbacks or fund growth internally. Even with lower recent debt, the capital structure remains stressed, increasing the importance of consistent cash generation and refinancing execution.

Community Health Business Overview & Revenue Model

Company Description

Community Health Systems, Inc. (CYH) operates as a major healthcare provider across the United States, focusing on the ownership, leasing, and management of general acute care hospitals. The organization offers a comprehensive array of medical servic...

Community Health Earnings Call Summary

Earnings Call Date:Oct 28, 2026(Q3-2026)|Next Earnings Date:Feb 17, 2027
Earnings Call SentimentNegative

The call included meaningful operational positives, including strong clinical quality, lower workforce turnover, growing clinic and imaging volumes, cost savings, improved cash flow, debt reduction, and continued investment in ambulatory capacity. However, the financial tone was pressured by a 7% core adjusted EBITDA decline, a lower EBITDA margin, unfavorable uninsured and commercial elective mix, elevated medical specialty costs, higher leverage, slower payer payments, declining self-pay collections, and reduced full-year guidance. Management also paused its medium-term targets and highlighted several 2027 uncertainties. Overall, the negative financial trends and outlook revisions outweighed the operational achievements.

Positive Updates

Improved Clinical Quality Performance
CHS further reduced severe sepsis and septic shock mortality rates and hospital-acquired infection metrics in the third quarter, continuing to outperform national benchmarks. The company also cited strong Leapfrog safety grades across its network.

Negative Updates

Third-Quarter Results Fell Below Internal Expectations
Third-quarter adjusted EBITDA was $280 million, with a 10.2% margin versus 12.2% in the prior-year period. Excluding divestitures and out-of-period items from the prior-year results, adjusted EBITDA reflected an approximate 7% core decline year over year.

Company Guidance

For full year 2026, net revenue is now expected to be $11.3 billion-$11.5 billion, adjusted EBITDA is expected to be $1.225 billion-$1.275 billion, or a 6.5% reduction at the midpoint, and cash flow from operations is expected to be $100 million-$300 million; fourth-quarter cash flow from operations is expected to be $85 million-$185 million, while capital expenditures are still expected to be between $350 million-$400 million. Year one awards under the Rural Health Transformation Program are expected to be $25 million-$30 million, with income recognized over a multiple year period starting in 2027. The 2027 outlook includes an out-of-period state-directed payment benefit of about a $15 million-$20 million net benefit in 2026 that won't repeat, a modest positive impact from Rural Health Transformation Program funds, another quarter of higher uninsured volumes, a potential moderate headwind in the fourth quarter of 2027 from the OBBBA funding cut to provider taxes, and medical specialties expected to continue to grow well above inflation next year. The full-year 2026 HIX disenrollment and movement to self-pay impact is now expected to be $80 million-$90 million, with the fourth quarter expected to be maybe $25 million-$30 million, and actions taken to date have a future benefit of something in that $100 million range, plus.

Community Health Risk Analysis

Community Health disclosed 74 risk factors in its most recent earnings report. Community Health reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Community Health Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CH:CG5 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ADUSADUS83Outperform$2.26B20.429.81%―11.53%27.72%
EHCEHC70Outperform$12.98B20.6325.17%0.58%9.36%20.78%
NHCNHC68Neutral$2.95B25.8810.41%1.37%5.71%12.44%
AVAHAVAH65Neutral$2.34B7.49115.53%―16.84%280.13%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%75%ADUSEHCNHCAVAHDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CH:CG5 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ADUSAddus HomeCare Corporation122.506.605.69%
EHCEncompass Health133.6521.3519.01%
NHCNational Healthcare190.7760.5946.55%
AVAHAveanna Healthcare Holdings Inc11.011.9721.79%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.